Lundbeck Inc. (formerly Ovation Pharmaceuticals)
Four Parkway North
Suite 200
Deerfield
Illinois
60015
U.S.A.
Phone:
800-455-1141
Fax:
847-282-1001
|
Lundbeck Inc., located in Deerfield, Illinois, was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by H. Lundbeck A/S in Copenhagen, Denmark. Lundbeck Inc. is a global biopharmaceutical company that develops and markets innovative medicines for severely ill patients with unmet medical needs. Lundbeck is unique in the pharmaceutical industry in that the company’s mission is to develop and sustain innovative medicines for severely-ill patients whose needs are not currently being met, rather than provide medicines for broad-based patient populations. One of the fastest growing companies in the pharmaceutical industry, Lundbeck combines a strong commercial drug portfolio with a robust late-stage development pipeline to serve patients who have limited or no other treatment options.
Lundbeck has a portfolio of 20 medicines – both approved and in development – with products available in more than 85 countries. The company focuses primarily on three therapeutic areas: central nervous system (CNS), hematology/oncology and hospital-based therapies/neonatal intensive care. Over the next three years, Lundbeck anticipates three new product launches in the United States. Fueled by the company’s robust and promising CNS pipeline, these new medicines will treat a variety of serious neurological conditions. Lundbeck’s existing products also have significant potential for other uses – and will make it possible for us to continue providing treatments for an increasing number of medical conditions where there remains unmet medical need.
By concentrating on investigational and approved drugs for focused patient populations where there is a significant need for treatment – including conditions like Lennox-Gastaut syndrome, Wilms’ tumor and acute intermittent porphyria, as well as broader epilepsies and cancers – the company fills an important void in the pharmaceutical industry. While not “blockbusters” by industry standards, our medicines take on blockbuster significance for certain patient populations where treatment options have been limited, but are no less essential.
What truly sets Lundbeck apart is the strong and growing demand for our products; our focus on bringing innovation to areas where few others are investing; the ability to effectively and efficiently bring new products to market; a uniquely balanced portfolio that combines a strong commercial base with one of the industry’s most robust late-stage central nervous system (CNS) pipelines; and a world-class management team.
Regardless of how Lundbeck grows, our success has always been driven by a meaningful purpose – to take care of and make a true difference in the lives of people. Through our daily work, we help people throughout the world by providing them access to effective medicines that might otherwise not be available.
Lundbeck's strategic focus on developing late-stage medicines that satisfy unmet medical needs – instead of developing "blockbusters" – has resulted in growth and success that far exceeds others companies of our size.
Our dedicated team of more than 300 pharmaceutical professionals, including an experienced team of clinical, regulatory and commercial experts, has a proven track record of working effectively with the FDA, developing and marketing high-need drugs that improve patients’ lives, and quickly and cost effectively bringing new products to market. Our operational excellence, diverse commercial portfolio and compelling development pipeline puts us in an excellent position for continued innovation and growth that will benefit patients for years to come.
Email:
info@lundbeck.com
Ownership:
Web Site:
Lundbeck Inc. (formerly Ovation Pharmaceuticals)
Employees:
Symbol:
|